8-K current report · filed Nov 5, 2026

ACCENDRA HEALTH INC/VA/ (ACH) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2ACH overview

Short answer

ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 and nine-month fiscal 2026 results released for periods ended September 30, 2026.

ACCENDRA HEALTH INC/VA/ 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 and nine-month fiscal 2026 results released for periods ended September 30, 2026
  • Press release issued November 5, 2026, containing the company’s financial results
  • Investors should review Exhibit 99.1 for revenue, profitability, cash flow and outlook details

Item 7.01 · Regulation FD Disclosure

  • Earnings presentation posted November 5, 2026 on Accendra Health’s Investor Relations website
  • Presentation provides supplemental investor information and is included as Exhibit 99.2
  • Investors should review Exhibit 99.2 for the company’s earnings details and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue fell to $601.8M from $697.3M, while adjusted EBITDA dropped to $47.8M from $92.2M
  • Continuing-operations adjusted EPS swung to a $0.23 loss from $0.25 income
  • Nine-month free cash flow turned negative at $(21.3)M versus $80.0M, increasing reliance on financing
  • Full-year revenue expected at the bottom of the $2.45B-$2.55B outlook, with adjusted EBITDA potentially 30% below the $310M midpoint
  • Liquidity tightened sharply: cash $26.6M versus $282.0M at December 31, while net debt reached $1.73B

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 continuing-operations revenue $602M, down from $697M after large commercial payor loss and cost pressures
  • Adjusted EBITDA $48M, down from $92M, reflecting volume declines, manufacturer cost increases and collection-rate pressure
  • Nine-month adjusted EBITDA $166M versus $285M, with free cash flow negative $21M versus positive $80M
  • Q3 free cash flow $6M despite $39M patient-service-equipment capex, while nine-month operating cash flow was negative $93M
  • Balance-sheet optimization generated $17M of debt-modification losses, including $16M in third-party fees, increasing near-term financing drag

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ACCENDRA HEALTH INC/VA/ 8-K filings

Get the next ACH 8-K as it lands

Follow ACH for push alerts, or ask the research agent what this filing means.